HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scott, F. W. Articles by Flohé, S. Search for Related Content PubMed PubMed Citation Articles by Scott, F. W. Articles by Flohé, S. Social Bookmarking                What's this?

Oral Exposure to Diabetes-Promoting Food or Immunomodulators in Neonates Alters Gut Cytokines and Diabetes

¹ Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada
² University of Ottawa, Ottawa, Ontario, Canada
³ Nutrition Research Division Health Canada, Ottawa, Ontario, Canada
⁴ Toxicology Research Division, Health Canada, Ottawa, Ontario, Canada
⁵ German Diabetes Research Institute, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany

Disease development in diabetes-prone BB rats is modified by the type of diet fed after weaning. The aim of this investigation was to determine whether exposure during the first week of life to antigens from a known diabetes-promoting diet (NIH-07) could modify diabetes incidence and, if so, to what extent this occurs via alterations in systemic T-cell reactivity, gut cytokines, or islet infiltration. Diabetes-prone BB (BBdp) rats were hand-fed twice daily between age 4 and 7 days with vehicle, a hydrolyzed casein (HC)–based infant formula, Pregestimil (PG), PG + cereal-based NIH-07 diet, PG + lipopolysaccharides (LPS) or PG + LPS + silica. After weaning, they were fed either an NIH-07 diet or a semipurified HC (diabetes-retardant) diet until 150 days. In separate studies, 5-day-old BBdp rat pups were administered the aforementioned treatments, and expression of intestinal mRNA for -interferon (IFN-) or transforming growth factor-ß (TGF-ß) was quantified using reverse transcriptase–polymerase chain reaction. The effect of early oral treatment with NIH-07 or PG on systemic T-cell reactivity was evaluated using footpad swelling delayed-type hypersensitivity (DTH) and the popliteal lymph node assay. Oral exposure of neonates to a complex mixture of antigens from the diabetes-promoting diet delayed onset of diabetes (79 vs. 88 days) and prevented disease in approximately one-third of animals. A similar protective effect was seen for neonatal exposure to wheat gluten in animals subsequently weaned onto a semipurified wheat gluten diet. By contrast, LPS-treated neonates displayed more severe insulitis and developed diabetes at an increased rate, which was significantly suppressed by co-administration of silica particles. The protective effect of early exposure to diabetogenic diets was not associated with significant reduction of islet infiltration, and there was no impact on the DTH response to food antigens. However, whereas diabetes-resistant BBc rats developed systemic tolerance to NIH-07 antigens fed chronically, BBdp rats did not. The lack of effect of the early oral antigen regimen on the DTH reaction in the footpad, a classic Th1-mediated reaction, suggests little effect on systemic T-cell reactivity. However, local effects were observed in the small intestine. Oral exposure to diabetes-promoting food antigens or LPS downregulated the Th1 cytokine IFN- and decreased the IFN-/TGF-ß ratio. Thus, oral exposure to diabetes-promoting food antigens and immune modulators in neonates can modify diabetes expression in association with changes in local cytokine balance in the gut.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				O. Vaarala, M. A. Atkinson, and J. Neu The "Perfect Storm" for Type 1 Diabetes: The Complex Interplay Between Intestinal Microbiota, Gut Permeability, and Mucosal Immunity Diabetes, October 1, 2008; 57(10): 2555 - 2562. [Abstract] [Full Text] [PDF]

				H. Ishikawa, H. Ochi, M.-L. Chen, D. Frenkel, R. Maron, and H. L. Weiner Inhibition of Autoimmune Diabetes by Oral Administration of Anti-CD3 Monoclonal Antibody Diabetes, August 1, 2007; 56(8): 2103 - 2109. [Abstract] [Full Text] [PDF]

				S. Ehrstrom, A. Yu, and E. Rylander Glucose in Vaginal Secretions Before and After Oral Glucose Tolerance Testing in Women With and Without Recurrent Vulvovaginal Candidiasis Obstet. Gynecol., December 1, 2006; 108(6): 1432 - 1437. [Abstract] [Full Text] [PDF]

				G.H.M. van Puijvelde, A.D. Hauer, P. de Vos, R. van den Heuvel, M.J.C. van Herwijnen, R. van der Zee, W. van Eden, T.J.C. van Berkel, and J. Kuiper Induction of Oral Tolerance to Oxidized Low-Density Lipoprotein Ameliorates Atherosclerosis Circulation, October 31, 2006; 114(18): 1968 - 1976. [Abstract] [Full Text] [PDF]

				S Graham, P Courtois, W J Malaisse, J Rozing, F W Scott, and A M. I Mowat Enteropathy precedes type 1 diabetes in the BB rat Gut, October 1, 2004; 53(10): 1437 - 1444. [Abstract] [Full Text] [PDF]

				S. Ma, Y. Huang, Z. Yin, R. Menassa, J. E. Brandle, and A. M. Jevnikar Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4 PNAS, April 13, 2004; 101(15): 5680 - 5685. [Abstract] [Full Text] [PDF]

				B. Rose, C. Herder, H. Loffler, H. Kolb, and S. Martin Combined activation of innate and T cell immunity for recognizing immunomodulatory properties of therapeutic agents J. Leukoc. Biol., April 1, 2004; 75(4): 624 - 630. [Abstract] [Full Text] [PDF]

				S. M Virtanen and M. Knip Nutritional risk predictors of {beta} cell autoimmunity and type 1 diabetes at a young age Am. J. Clinical Nutrition, December 1, 2003; 78(6): 1053 - 1067. [Abstract] [Full Text] [PDF]

				J. M. Norris, K. Barriga, G. Klingensmith, M. Hoffman, G. S. Eisenbarth, H. A. Erlich, and M. Rewers Timing of Initial Cereal Exposure in Infancy and Risk of Islet Autoimmunity JAMA, October 1, 2003; 290(13): 1713 - 1720. [Abstract] [Full Text] [PDF]

				M. Westerholm-Ormio, O. Vaarala, P. Pihkala, J. Ilonen, and E. Savilahti Immunologic Activity in the Small Intestinal Mucosa of Pediatric Patients With Type 1 Diabetes Diabetes, September 1, 2003; 52(9): 2287 - 2295. [Abstract] [Full Text] [PDF]

				M. Peppa, C. He, M. Hattori, R. McEvoy, F. Zheng, and H. Vlassara Fetal or Neonatal Low-Glycotoxin Environment Prevents Autoimmune Diabetes in NOD Mice Diabetes, June 1, 2003; 52(6): 1441 - 1448. [Abstract] [Full Text] [PDF]